Novo Nordisk launches one-weekly diabetes treatment in UK

Ozempic, a new once-weekly GLP-1 analogue injection aimed at type 2 diabetes from Novo Nordisk, is no available in the UK.

Ozempic (semaglutide) works by mimicking the function of the GLP-1 (human glucagon-like peptide-1) hormone produced in the gut that lowers post-meal blood glucose levels and also slows glucose absorption into the bloodstream.

The treatment should be used alongside diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications or in addition to other medicinal products for the treatment of diabetes, when type 2 diabetes is insufficiently controlled.

Dr Avideh Nazeri, Director of Clinical, Medical and Regulatory for Novo Nordisk UK, said: “Novo Nordisk is proud to bring Ozempic to people living with type 2 diabetes in the UK. We believe the clinical profile of Ozempic will help to meet the real and serious needs of those living with this condition.”

Ozempic has received positive recommendation by the two UK health technology assessment bodies – All Wales Medicines Strategy Group (AWMSG) and Scottish Medicines Consortium (SMC).

The treatment is recommended as a treatment option for restricted use within NHS Wales and NHS Scotland in the treatment of insufficiently controlled type 2 diabetes mellitus in adults as an add-on therapy to oral antidiabetic medicines or basal insulin.

Help us maintain our standards of journalism

Readers enjoy our news site but keeping our news up to date and authoritative, without charging readers to view the site is a challenge. Especially now with the Corona Virus measures affecting us all, as many clients have been severely affected and are naturally reducing their spend on advertisements. Given this lack of revenue stream we are calling on the generosity of our readers to help us fill that void and enable our journalists to continue delivering the news that you enjoy.

Unlike many other news sites, we don't have annoying pop ups or charge scandalous prices for events. We also produce magazines for each title and make these freely available to read online, for your enjoyment. Often, people have asked why we don't make a charge for viewers to read these magazines and news stories but we feel that would adversely affect our readership/advertisers response rate. But with advertising revenues now severely affected we need your help. So, if you can support our news sites/magazines with a small donation of even £1 your generosity will help us weather the current storm and continue in our quest to deliver quality journalism.

We value your readership and your support, as this enables us to continue to provide our regular daily news updates. We've been established over 30 years, during which we've lost count of the numerous recessions and financial meltdowns, and we intend to weather the storms caused by Covid-19. So, every reader contribution, however big or small, is invaluable in helping us to get through this. Please click here to help support your favourite news site/magazine.

- Advertisement -

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Inovio publishes positive data on COVID-19 DNA vaccine

Inovio has published preclinical study data for IN0-4800 –  its COVID-19 DNA vaccine – demonstrating robust neutralising antibody and T cell immune responses against...

mRNA-based vaccine tech emerging as frontrunner against COVID-19

Messenger RNA (mRNA) based vaccine technology is emerging as one of the frontrunners among the technologies being evaluated to develop a vaccine for COVID-19,...

Tecentriq gains first-line approval in NSCLC

The FDA has approved Roche’s Tecentriq (atezolizumab) as a first-line monotherapy for the treatment of metastatic non-small cell lung cancer (NSCLC), marking its fourth...

Related news

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Inovio publishes positive data on COVID-19 DNA vaccine

Inovio has published preclinical study data for IN0-4800 –  its COVID-19 DNA vaccine – demonstrating robust neutralising antibody and T cell immune responses against...